Journal of Cardiac Failure
Volume 16, Issue 3 , Pages 260-267 , March 2010

The Effect of Renin-Angiotensin System Inhibitors on Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: A Systematic Review and Meta-Analysis

  • Ravi V. Shah, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Akshay S. Desai, MD, MPH

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • ,
  • Michael M. Givertz, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
    • Harvard Medical School, Boston, MA
    • Corresponding Author InformationReprint requests: Michael M. Givertz, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Tel: 617-732-7367; Fax: 617-264-5265.

Received 30 July 2009 ,Revised 25 November 2009 ,Accepted 30 November 2009.

References 

  1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146
  2. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol. 1995;26:1565–1574
  3. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004;43:317–327
  4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. for the CHARM Investigators and Committees Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction (CHARM-Preserved) trial. Lancet. 2003;362:777–781
  5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. for the I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467
  6. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345
  7. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJ, Granger CB, et al. for the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators Influence of non-fatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116:1482–1487
  8. Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, et al. The Hong Kong diastolic heart failure study: a randomized controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94:573–580
  9. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016
  10. Benedict CR, Francis GS, Shelton B, Johnstone DE, Kubo SH, Kirlin P, et al. and the SOLVD Investigators Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol. 1995;75:1151–1157
  11. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, et al. for the SOLVD Investigators Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation. 1993;88:2277–2283
  12. Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol. 1993;22:146A–153
  13. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685–691
  14. McEwan PE, Gray GA, Sherry L, Webb DJ, Kenyon CJ. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation. 1998;98:2765–2773
  15. Ramires FJ, Sun Y, Weber KT. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. J Am Coll Cardiol. 1998;30:475–483
  16. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865–879
  17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardio vascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med. 2000;342:145–153
  18. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800–2806
  19. Devereux RB, Dahlof B, Gerdis E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456–1462
  20. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, et al. Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079–2087
  21. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation. 2008;118:2183–2189
  22. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759–776
  23. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor inhibitor valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675

 R.V.S. has received fellowship support from the National Institutes of Health, National Heart, Lung and Blood Institute Heart Failure Clinical Research Network (U01 HL084904).

PII: S1071-9164(09)01194-4

doi: 10.1016/j.cardfail.2009.11.007

Journal of Cardiac Failure
Volume 16, Issue 3 , Pages 260-267 , March 2010

Article Tools

* Image Usage & Resolution